Literature DB >> 30478807

Fertility preservation in women with malignancies: the accuracy of antral follicle count collected randomly during the menstrual cycle in predicting the number of oocytes retrieved.

Francesca Filippi1, Fabio Martinelli2, Alessio Paffoni1, Marco Reschini1, Francesco Raspagliesi2, Edgardo Somigliana3,4,5.   

Abstract

PURPOSE: To evaluate the capacity of random antral follicle count (AFC), i.e., AFC recorded at any time during the menstrual cycle, to predict the number of retrieved mature oocytes in women with malignancies undergoing random start ovarian hyperstimulation
METHODS: A consecutive series of 72 women with malignancies who underwent ovarian hyperstimulation aimed at egg freezing between July 2014 and December 2016 was retrospectively reviewed. A standardized random start protocol was used for all women. AFC and serum AMH were systematically assessed prior to initiating ovarian hyperstimulation. The main outcome was the retrieval of ≥ 10 mature oocytes. The accuracy of random AFC was tested with the c-statistics (area under the ROC curve).
RESULTS: For the whole cohort, the c-statistics for the prediction of ≥ 10 mature oocytes using AFC and serum AMH were similar. Specifically, the areas under the curve were 0.76 (95%CI 0.66-0.87) and 0.82 (95%CI 0.72-0.92), respectively (p = ns). Moreover, when considering the subgroup of women recruited after day 5 of the cycle (proper random start, n = 52), the areas under the curve did not also differ. Specifically, they resulted in 0.77 (95%CI 0.64-0.89) and 0.83 (95%CI 0.72-0.95), respectively (p = ns).
CONCLUSIONS: AFC collected at any time during the menstrual cycle can provide valuable information for the counseling of women with malignancies scheduled for oocyte cryopreservation. Its reliability appears to be non-inferior to that of serum AMH.

Entities:  

Keywords:  AMH; Antral follicle count; Fertility preservation; Oocyte; Random start

Mesh:

Year:  2018        PMID: 30478807      PMCID: PMC6439113          DOI: 10.1007/s10815-018-1377-0

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  36 in total

1.  The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration.

Authors:  Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; David Moher; Drummond Rennie; Henrica C W de Vet; Jeroen G Lijmer
Journal:  Ann Intern Med       Date:  2003-01-07       Impact factor: 25.391

2.  The predictive value of antral follicle count remains unchanged across the menstrual cycle.

Authors:  Luk Rombauts; Joseph L Onwude; Hong W Chew; Beverley J Vollenhoven
Journal:  Fertil Steril       Date:  2011-10-20       Impact factor: 7.329

Review 3.  The antral follicle count: practical recommendations for better standardization.

Authors:  Frank J M Broekmans; Dominique de Ziegler; Colin M Howles; Alain Gougeon; Geoffrey Trew; Francois Olivennes
Journal:  Fertil Steril       Date:  2009-07-08       Impact factor: 7.329

4.  Consistent and predictable delivery rates after oocyte vitrification: an observational longitudinal cohort multicentric study.

Authors:  Laura Rienzi; Ana Cobo; Alessio Paffoni; Claudia Scarduelli; Antonio Capalbo; Gábor Vajta; José Remohí; Guido Ragni; Filippo Maria Ubaldi
Journal:  Hum Reprod       Date:  2012-03-22       Impact factor: 6.918

5.  Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone.

Authors:  Sanghoon Lee; Sinan Ozkavukcu; Elke Heytens; Fred Moy; Rose M Alappat; Kutluk Oktay
Journal:  J Assist Reprod Genet       Date:  2011-05-04       Impact factor: 3.412

Review 6.  Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications.

Authors:  Monika L Metzger; Lillian R Meacham; Briana Patterson; Jacqueline S Casillas; Louis S Constine; Nobuko Hijiya; Lisa B Kenney; Marcia Leonard; Barbara A Lockart; Wendy Likes; Daniel M Green
Journal:  J Clin Oncol       Date:  2013-02-04       Impact factor: 44.544

Review 7.  Biomarkers of ovarian response: current and future applications.

Authors:  Scott M Nelson
Journal:  Fertil Steril       Date:  2013-01-08       Impact factor: 7.329

8.  Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts.

Authors:  J van Disseldorp; C B Lambalk; J Kwee; C W N Looman; M J C Eijkemans; B C Fauser; F J Broekmans
Journal:  Hum Reprod       Date:  2009-10-19       Impact factor: 6.918

Review 9.  Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART).

Authors:  A La Marca; G Sighinolfi; D Radi; C Argento; E Baraldi; A Carducci Artenisio; G Stabile; A Volpe
Journal:  Hum Reprod Update       Date:  2009-09-30       Impact factor: 15.610

10.  Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach.

Authors:  Simone L Broer; Jeroen van Disseldorp; Kimiko A Broeze; Madeleine Dolleman; Brent C Opmeer; Patrick Bossuyt; Marinus J C Eijkemans; Ben-Willem J Mol; Frank J M Broekmans
Journal:  Hum Reprod Update       Date:  2012-11-27       Impact factor: 15.610

View more
  3 in total

1.  Oocyte cryopreservation in two women with borderline ovarian tumor recurrence.

Authors:  Francesca Filippi; Fabio Martinelli; Edgardo Somigliana; Dorella Franchi; Francesco Raspagliesi; Valentina Chiappa
Journal:  J Assist Reprod Genet       Date:  2020-03-04       Impact factor: 3.412

2.  Clinical Outcomes of In Vitro Maturation After Oocyte Retrieval With Gynecological Surgery for Refractory Polycystic Ovary Syndrome: A Retrospective Cohort Study.

Authors:  Wen Zhang; Tingting Liang; Bing Han; Rui Yang; Shuo Yang; Yan Yang; Jiajia Zhang; Xiaoying Zheng; Jie Yan; Caihong Ma; Xueling Song; Jie Qiao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-04       Impact factor: 5.555

Review 3.  The Clinical Value and Interpretation of Anti-Müllerian Hormone in Women With Cancer.

Authors:  Richard A Anderson; H Irene Su
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-07       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.